Wyoming, MINCT06402968Now EnrollingIRB Ready

Intracerebral Hemorrhage Clinical Trial in Wyoming, MI

Access cutting-edge intracerebral hemorrhage treatment through this clinical trial at a research site in Wyoming. Study-provided care at no cost to qualified participants.

Sponsored by Zeenat Qureshi Stroke Institute

Quick Self-Assessment

See if you qualify for this Wyoming location

Preparing your pre-screening questions…

Expert Care in Wyoming

Access intracerebral hemorrhage specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related intracerebral hemorrhage treatment provided free

Apply for This Wyoming Location

Check if you qualify for this intracerebral hemorrhage clinical trial in Wyoming, MI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Wyoming

    Convenient for MI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Wyoming site if eligible
  4. 4Begin participation

About This Intracerebral Hemorrhage Study in Wyoming

The aim is to compare the rate of hypertensive subjects with ICH who reach SBP target with stability within 60 minutes of enrollment, among patients treated with IV clevidipine with those treated with alternate IV antihypertensive regimen.

Sponsor: Zeenat Qureshi Stroke Institute

Who Can Participate

Inclusion Criteria

Age 18 years or older and less than 100 years.
Onset of new neurological deficits within 12 hours at the time of enrollment and IV clevidipine or alternate IV antihypertensive regimen can be initiated within 12 hours of symptom onset.
Clinical signs consistent with the diagnosis of stroke, including impairment of language, motor function, cognition, and/or gaze, vision, or neglect.
Initial National Institutes of Health Stroke Scale (NIHSS) score of 1 or greater.
Total GCS score (aggregate of verbal, eye, and motor response scores) of 5 or greater at enrollment
Computed Tomography (CT) scan of the brain demonstrates intraparenchymal hematoma with manual hematoma volume measurement \>5 cc (excluding microhemorrhages)
Admission SBP greater than and equal to 150 mmHg but less than 220 mmHg on two repeat measurements at least 5 minutes apart, but no more than 10 minutes apart. The reason for

Exclusion Criteria

of ICH patients with initial SBP ≥220 mm Hg is based on a post hoc analysis of ATACH-2, which found that patients with initial SBP ≥220 mm Hg (22.8% of the cohort) reported higher rates of neurological deterioration at 24 hours and renal adverse events until day 7 or discharge in patients treated with intensive SBP reduction compared with standard SBP lowering, without any benefit in reducing hematoma expansion at 24 hours or death or severe disability at 90 days.
Signed and dated informed consent by subject, legally authorized representative, or surrogate before index hospital discharge for data collection and agreement to participate in 90- and 180-day follow-up visits.
Patients with anticoagulant-related ICH are eligible as long as anticoagulant reversal is concurrently undertaken consistent with AHA/ASA guidelines.
Patients who will undergo surgical evacuation consistent with AHA/ASA guidelines or local institutional guidelines are eligible unless surgical evacuation is being performed within 6 hours of initiation of IV clevidipine or alternate IV antihypertensive medication regimen. Ultra-early surgery will necessitate use of anesthetic agents which will confound the effect of IV clevidipine or alternate IV antihypertensive medication regimen. Ultra-early surgery/intervention was not used in the minimally invasive catheter evacuation followed by thrombolysis (MISTIE)/ Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage (CLEAR) trials, which required ICH patients to undergo a repeat CT scan after 6 hours to document absence of any hematoma expansion (with ≤5 mL hematoma growth) compared to a previous CT scan prior to any surgical intervention.
Patients requiring external ventricular drainage consistent with AHA/ASA guidelines or local institutional guidelines are eligible. Exclusion Criteria
Time of symptom onset cannot be reliably assessed.
Previously known neoplasms, arteriovenous malformation (AVM), or aneurysms.
Intracerebral hematoma considered to be related to trauma.
ICH located in infratentorial regions such as pons or midbrain (cerebellar ICH is not an exclusion criteria).
Subject considered a candidate for immediate surgical intervention by the neurosurgery service.
Pregnancy, parturition within previous 30 days, or active lactation.
Any history of bleeding diathesis or coagulopathy except anticoagulant related ICH.
Platelet count of less than 50,000/mm3.
Known sensitivity to nicardipine or clevidipine.
Patient's living will precludes aggressive ICU management.
Patients with allergies to soybeans, soy products, eggs, or egg products.
Defective lipid metabolism such as pathologic hyperlipemia, lipoid nephrosis, or acute pancreatitis if it is accompanied by hyperlipidemia.
Patients with severe aortic stenosis.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Wyoming?

Yes, this clinical trial (NCT06402968) has an active research site in Wyoming, MI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Intracerebral Hemorrhage Treatment Options in Wyoming, MI

If you're searching for intracerebral hemorrhage treatment options in Wyoming, MI, this clinical trial (NCT06402968) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Wyoming research site is actively enrolling participants for this clinical trial. You'll receive care from experienced intracerebral hemorrhage specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all intracerebral hemorrhage clinical trials near you to find additional studies recruiting in your area.

More Rheumatoid Arthritis Trials in Wyoming, MI

See all rheumatoid arthritis clinical trials recruiting in Wyoming — not just this study.

Browse Rheumatoid Arthritis Trials in Wyoming →

Browse More Trials by Condition

Rheumatoid Arthritis TrialsAll Conditions →

Ready to Join in Wyoming?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Wyoming, MI